The study found no significant difference in the rates of SARS-CoV-2 infection, pneumonia, or hospitalization between AR patients receiving AIT and those not receiving AIT, suggesting that AIT does not increase the risk of COVID-19 infection.
Early introduction of specific foods (peanut, cooked egg) likely reduces the risk of developing food-specific allergies, while evidence for other allergic outcomes remains uncertain.
Treatment with high-dose Tacrosolv resulted in a significant reduction in Total Ocular Symptom Score (TOSS) and intensity of ocular symptoms like redness and watery eyes, as well as a reduction in total nasal symptoms such as itching and sneezing.
Patients treated with GBM AIT showed a significant reduction in the use of anti-allergic nasal sprays during the pollen season, particularly in the first 0-5 years after treatment, indicating long-term effectiveness of the therapy.
The intervention led to a significant reduction in penicillin allergy labels and increased prescribing of beta-lactams in the 6 months following the intervention.
The study found that anti-PEG IgE was not predominantly present in patients who experienced anaphylaxis after vaccination, suggesting that it may not be a significant mechanism for these reactions.
The study demonstrated that machine learning can accurately predict free IgE concentration, aiding in the diagnosis and monitoring of allergic diseases.
The study found that children with food allergies exhibited distinct metabolomic profiles, with higher levels of certain bile acids and histidines associated with sustained unresponsiveness. Metabolites like lithocholic acid and urocanic acid were linked to improved outcomes in OIT, indicating their potential role in achieving long-term tolerance.
Successful POIT was associated with a distinct gut microbiome profile, characterized by lower microbial diversity and specific bile acid profiles that promote immunological tolerance. Children who achieved remission exhibited a microbiome that supported amino acid biosynthesis and reduced allergenic peptide metabolism.
The study concluded that patients with allergic diseases do not have an increased risk for systemic side effects after receiving COVID-19 vaccines, indicating that vaccination is safe for this population.
The treatment significantly improved nasal airflow and reduced nasal secretion compared to saline solution, with 61% of participants showing increased airflow after treatment.
The study found that combined treatment led to significant hypermethylation of genes related to immune function, suggesting a potential reduction in allergy development. The double-treated group exhibited unique methylation patterns, indicating synergistic effects of the interventions.
The study identifies significant gene-metabolite associations that may help in understanding the biological pathways influencing total IgE levels, potentially leading to improved treatment strategies for pediatric asthma.
The study found that TZD significantly modulates immune responses and enriches immune-related microbiomes, leading to improved symptoms of allergic rhinitis and a better understanding of its mechanisms through multi-omics validation.
Prophylactic treatment with Callergin significantly reduced the total nasal symptom score (TNSS) compared to no treatment, particularly for rhinorrhea and congestion.
The study concluded that vaccination of allergic individuals is generally recommended, as no cases of anaphylaxis were diagnosed despite some participants visiting the emergency room after vaccination.
AM-301 demonstrated noninferiority to HPMC in reducing total nasal symptom scores (TNSS) and was rated as good or very good by 31% of subjects compared to 14% for HPMC.
The clinical trials demonstrated significant reductions in symptoms of allergic rhinitis, including runny nose, nasal congestion, and itching. In one study, the prevalence of rhinorrhea, nasal congestion, and decreased smell was significantly lower in the spirulina group compared to the control group.
The study found a significant decrease in pediatric asthma patients during the COVID-19 pandemic, indicating a potential impact of environmental changes and healthcare access on asthma management.
AllergoEye demonstrated high sensitivity (98%) and specificity (90%) in detecting allergic reactions compared to human estimations. The specificity could be increased to 97% by tuning the cut-off threshold, and a correlation was found between detected sensitivity to allergens and sIgE CAP-class.
Increased eosinophil and lymphocyte counts in bronchoalveolar lavage fluid after allergen challenge, with significant increases in Th2 cytokines. GSTM1-null subjects showed reduced inflammatory responses to allergen after ozone exposure.
Identification of a novel genetic locus associated with early-onset persistent wheeze and the potential for targeted therapies that could improve management of this condition.
Significant reduction in defects on ventilation and perfusion maps after treatment (p<0.01) and increased mean ventilation signal intensity (VSI_mean) after treatment (p<0.01).
The study demonstrated that RSV immunoprophylaxis during infancy has long-term effects on nasal epigenetic signatures at age 6, which are related to host antiviral defense pathways.